Johnson & Johnson

Biomet has an exclusive, binding offer of $280M on the table for J&J’s DePuy Trauma division. The deal is thought to represent J&J’s concession, extracted from the leviathan by an EU commission, in order to ratify its $21Bn takeover of Synthes.

Vaginal Mesh problems are going to land at someone’s door and J&J’s looking like a soft target. It transpires the company decided to launch “Prolift” in 2005 as an “insignificant change” to a previous device, so didn’t feel the need to tell FDA about it.

According to sources “familiar with the matter”, Johnson and Johnson’s acquisition of Synthes, first announced last year, is now likely to gain approval from the European Commission following its investigation and concession from J&J.

Ethicon-Endo-supported retrospective data study says VATS is cheaper and better than open wedge resection.

J&J appoints CEO from within. Outgoing Weldon becomes Chairman of Board of Directors

Johnson & Johnson DePuy sees fit to respond to New York Times article it claims to contain untruths regarding how it behaved during the all-metal implant situation.

A new article in the New York times suggests J&J DePuy were wrong in continuing to sell product overseas after FDA raised concerns. If that happened every time FDA demanded more clinicals we might as well harmonise.

You say sirolimus, I say everolimus… judge says lets call the whole thing off.

It’s all good news for J&J as another of its divisions faces a telling off from FDA.

FDA has announced a heightened degree of scrutiny regarding transvaginally inserted meshes and is considering reclassifying from Class II to Class III.

Richard Bohner, ex VP of Synthes has now been sentenced to 8 months in prison for his role in the illegal human trials of what was an experimental bone cement.

Former Synthes executives Michael Huggins and Thomas Higgins were sentenced Monday to nine months in prison with three months probation and a $100,000 fine for illegal promotion of Norian products.

FDA is taking a proactive stance and working with manufacturers to understand the issue of longitudinal compression in next generation Drug-Eluting Stents.

Ethicon Endo-Surgery, Inc. has announced U.S. FDA 510(k) clearance of its innovative ENSEAL® G2 Curved and Straight Tissue Sealers

The European Commission has opened an in-depth investigation under the EU Merger Regulation into the planned acquisition of Synthes Inc. by Johnson and Johnson, both US companies active in the area of orthopaedic medical devices.

Two new endoscopic devices launched in the UK promise to improve the success of surgery for treatment of chronic sinusitis.